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Low Baseline Pneumococcal Antibody
Titers Predict Specific Antibody Deficiency,
Increased Upper Respiratory Infections,
and Allergy Sensitization
Charles H. Song, MD1 , Dennys Estevez, MPH2,
Diana Chernikova, MD, PhD3, Francesca Hernandez, MD3,
Rie Sakai-Bizmark, MD2, and Richard Stiehm, MD4
Abstract
Background: Inadequate titers of pneumococcal antibody (PA) are commonly present among patients with recurrent
respiratory infections.
Objective: We sought to determine the effect of the degree of inadequacy in baseline PA titers on the subsequent
polysaccharide vaccine response, the incidence of sinusitis, and allergic conditions.
Methods: A total of 313 patients aged 6 to 70 years with symptoms of recurrent respiratory infections were classified
by baseline-pPA (percentage of protective [1.3 mg/mL] PA serotypes/total tested serotypes) and postvaccination pPA (post-
pPA): Group A (adequate baseline-pPA), Group B (inadequate baseline-pPA, adequate post-pPA, responders), and Group C
(inadequate baseline-pPA, inadequate postpPA, nonresponders, specific antibody deficiency [SAD]). Immunity against
Streptococcus pneumoniae was defined as adequate when the pPA was 70%. Each group and combined groups, Group
AB (inadequate baseline-pPA), and Group BC (adequate post-pPA) were analyzed for demographics, history of sinusitis,
recurrent sinusitis in the following year, allergic conditions, and association with inadequate individual serotype titers.
Results: Over 80% of patients with respiratory symptoms had inadequate baseline-pPA. Baseline-pPA and SAD prevalence
are inversely related (odds ratio¼ 2.02, 95% CI: 1.15–3.57, P¼.01). Inadequate serotype 3 antibody titer is highly associated
with SAD (odds ratio¼ 2.02, 96% CI: 1.61–5.45, P<.01). The groups with inadequate pPA (Group B and C, or BC) had
significantly higher percentage of patients with chronic rhinosinusitis (P<.001), allergic sensitization, and allergic rhinitis
(P<.05). Group A contained higher percentage of patients with recurrent upper airway infections (P<.001).
Conclusion: Low baseline-pPA and low antibody titers to serotype 3 are highly associated with SAD, increased incidence of
respiratory infections including CRS and allergic conditions.
Keywords
specific antibody deficiency, asthma, allergic rhinitis, recurrent respiratory infection, immune deficiency, sinusitis, chronic
rhinosinusitis
It is known that patients with recurrent respiratory
infections may have inadequate pneumococcal antibody
(PA) titers representing poor state of defense against
polysaccharide bacteria.1–3 For these patients, polysac-
charide pneumococcal vaccine (PPV) is recommended
for evaluation and boosting of independent humoral
immunity.4 Subjects with inadequate vaccine response,
but with normal levels of immunoglobulins and IgG
subclasses in the absence of other primary or secondary
immunodeficiencies, are classified as having specific
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antibody deficiency (SAD).4–6 Although the guidelines
by the working group of experts consider vaccine
responses of PA titer> 1.3 ng/mL in <70% of total
tested PAs for patients aged 6 to 65 years as inadequate
response (SAD),4,5 there is still controversy as to what
constitutes adequate immune state. The immune state of
a patient at a given time needs to reflect PA titers result-
ing from both vaccination and responses from natural
exposures to Streptococcus pneumoniae. The evaluation
of a response to polysaccharide antigen involves assess-
ment of the concentration and function of each antibody
to diverse serotypes of varying immunogenicity. Even
the accuracy of PA testing methods has been ques-
tioned.7,8 Although previous studies mainly reported
association between chronic rhinosinusitis (CRS) and
SAD, we broadened our study to include patients with
not only CRS but chronic respiratory symptoms. The
goal of our study was to find the relationship between
the antibody titers of commonly tested serotypes result-
ing from both vaccination and natural exposures, as an
individual and as a group, and the clinical conditions in
a time line surrounding the initial and vaccination visits.
Methods
Study Design
This retroactive study was performed using electronic
medical chart review of patients seen between 2008 and
2018 at an allergy-immunology clinic in Los Angeles,
California. This study was approved by the
Institutional Review Board and Human Subjects
Committee at LA Biomedical Institute at Harbor-
UCLA Medical Center.
As all patients who presented with recurrent respira-
tory symptoms were screened with PA profiles, the
Current Procedural Terminology code for PA testing
was used for initial capture of the study population.
These charts were further reviewed for the inclusion
and exclusion criteria. Patients aged 6 to 70 years were
included if they had history suggesting respiratory infec-
tion: chronic cough (>4 weeks), persistent rhinitis
(>4 weeks), chronic sinusitis (CRS; >12 weeks), and
recurrent acute sinusitis (RAS; >1 time/year). Patients
with history of malignancy, autoimmune disorder, or
primary/secondary immunodeficiency were excluded.
Classification of the Subjects’ Clinical Conditions
The diagnosis of sinusitis was made when a patient met
the widely used criteria9 of positive history of sinusitis
and nasal endoscopy or sinus CT scan. Sinusitis was
classified into acute or chronic sinusitis using 12 weeks’
duration as the threshold. Since many patients had both
chronic and acute sinusitis at separate times, the CRS
category was defined as CRS with or without acute
sinusitis. RAS was defined as >1 episode of acute sinus-
itis/year without CRS. Recurrent upper airway infection
(RU) was defined as upper respiratory infection (URI)
symptoms lasting <2 weeks occurring >4 times/year.
Symptoms suggestive of sinusitis without meeting the
criteria were categorized as no infection (NI) category.
There was only 1 patient with a diagnosis of pneumonia
in the study and was excluded from the analysis.
Classification of the Subjects’ Immune Status by
Laboratory Testing
Immune status was evaluated with levels of immunoglo-
bulins (Igs) G, A, M, and E, and of IgG antibodies to S.
pneumoniae and Clostridium tetani (Luminex Assay, by
LabCorp for 89% of the patients and Quest Diagnostics
for the rest). Baseline and subsequent tests were per-
formed by the same laboratory. In patients evaluated
prior to 2010, 14 serotypes were reported: 1, 3, 4, 5, 8,
9(9N), 12(12F), 14, 19(19F), 23(23F), 26(6B), 51(7F), 56
(18C), and 68(9V). After 2010, 23 serotypes were
reported: 1, 3, 4, 8, 9(9N), 12(12F), 14, 17(17F), 19
(19F), 2, 20, 22(22F), 23(23F), 26(6B), 34(10A), 43(12),
5, 51(7F), 54(15B), 56(18C), 57(19A), 68(9V), and
70 33F). Based on the consensus by the American
Academy of Allergy, Asthma & Immunology working
group,4,5 a protective PA titer was defined as
1.3 mg/mL; percentage of protective PA (pPA) 70%
were considered adequate regardless of history of prior
immunization with either unconjugated (polysaccharide
pneumococcal vaccine [PPV]-23) or conjugated vaccine
(pneumococcal conjugated vaccine [PCV]-7 or -13).
Thereafter, patients were divided into 3 groups: A (ade-
quate baseline-pPAs), B (inadequate baseline-PAs with
adequate post-PAs, responders), and C (inadequate
baseline- and post-PAs, SAD) (see Figure 1). Group C
was treated with PCV and tested for postvaccinating PA
titers. These groups were also analyzed as combinations:
Group AB (Group A and Group B, non-SAD) versus
Group C (SAD) as well as Group A (adequate baseline-
pPA) versus Group BC (Group B and Group C, inade-
quate baseline-pPA).
Evaluation of Subjects’ Allergic Conditions
Allergy skin tests were performed using 16-40 standard
indoor and outdoor inhalant allergens present in
Southern California. Total serum IgE and specific IgEs
to inhalant allergens for Southern California (LabCorp,
Burlington, North Carolina) were used to detect the kind
and degree of sensitization. The diagnosis of asthma or
rhinitis was based on the relevant ICD 9 or 10 code or
clinical history. Allergic designation of these diagnoses
was based on the presence of positive reaction to any
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allergen(s) on the skin test or in the laboratory report of
specific serum IgE.
Statistical Analysis
Patient characteristics were described by individual
groups, A, B, and C, and as combined groups, AB and
BC. Median, interquartile markers, and Mann–Whitney
test results were reported for continuous variables while
frequencies, column percentages, and v2 test results were
reported for categorical variables. A multivariable logis-
tic regression model was used to determine the associa-
tions between the outcomes Group C versus Group AB,
Group A versus Group BC, and the variables (age, CRS,
All paents                                          
n=313
Baseline pPA test
PPV > Post-pPA ter
(> 4weeks aer baseline test)     
GROUP A            
Baseline-
pPA≥70%  n=58
GROUP B+C       
Baseline-
pPA<70% n=255
GROUP B     
post-pPA ≥70%, 
n=193
GROUP C (SAD)     
post –pPA<70% 
n=62
Figure 1. Flow chart of all patients classified by baseline and post-pPA (post-vaccination percentage of protective pneumococcal anti-
body). Group A, adequate baseline-pPA; Group B, inadequate baseline-pPA with adequate post-pPA; Group C, inadequate post-pPA, SAD;
pPA¼ percentage of protective (1.3 mg/mL) pneumococcal antibody serotypes to total tested serotypes; PPV, polysaccharide pneumo-
coccal vaccine; SAD, specific antibody deficiency.
Table 1. Demographics and Clinical/Laboratory Characterization of Study Subjects by Postvaccination Responses.
Number
of Patients
(% of total
patient number)
Group A:
Adequate
baseline-pPA
Group B:
Adequate
post-pPA
Group C:
Inadequate
post-pPA (SAD)
Total P
Value
P Value:
Group A vs
Group B
P Value:
Group A
vs Group C
P Value:
Group B
vs Group C
Patient cohort (%) 313 58 (19) 193 (62) 62 (20)
Median age 34 31 35 41 .02 .54 .06 .006
Ethnicity (white /other) 268/45 51/7 163/30 54/8 .75 .51 .89 .62
Male/female 111/202 15/43 73/120 23/39 .24 .09 .18 .91
Recurrent infection (%) 241 (77) 43 (74) 146 (76) 52 (84) .35 .81 .19 .18
No infection (%) 72 (23) 15 (26) 47 (24) 10 (14) .35 .81 .19 .18
Chronic rhinosinusitis (%) 143(45) 15 (26) 91 (47) 37 (60) .0008 .04 .0002 .08
Recurrent acute sinusitis (%) 61 (24) 12 (21) 38 (20) 11 (18) .91 .87 .68 .74
Recurrent upper
respiratory infection (%)
37(12) 16 (27) 17 (9) 4 (6) .03 .0002 .002 .56
Allergy sensitization (%) 194 (62) 29 (50) 128 (66) 37 (60) .07 .02 .29 .34
Asthma (%) 134 (43) 25 (43) 81 (42) 28 (45) .90 .88 .82 .66
Allergic asthma (%) 100 (32) 13 (22) 66 (34) 21 (34) .23 .09 .16 .96
Rhinitis (allergic and
nonallergic) (%)
242 (77) 43 (74) 153 (79) 46 (74) .58 .41 .99 .4
Allergic rhinitis (%) 177 (57) 26 (45) 120 (62) 31 (50) .03 .019 .5 .08
Abbreviations: pPA, percentage of protective (1.3mg/mL) pneumococcal antibody serotypes/total tested serotypes; SAD, specific antibody deficiency.
Bold values indicate statistical significance (P<.05). Baseline-pPA denotes prevaccination pPA and post-pPA denotes postvaccination pPA.
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RAS, RU, allergy sensitization, asthma [allergic vs non-
allergic], rhinitis [allergic vs nonallergic], and individual
serotypes). Multivariable logistic regression models were
also utilized to determine the association between
baseline-pPA values and the patients’ response to PPV
(SAD as an outcome), and the difference in the recur-
rence rate of sinusitis in 1-year follow-up (outcome)
among the 3 groups. SAS version 9.4 (Cary, North
Carolina) was used for all analyses.
Results
Patient Demographics, Prevalence of SAD,
and Other Clinical Conditions
A total of 313 patients with recurrent respiratory symp-
toms were studied; the median age was 34 years with 86%
whites and 64% females (Table 1). Patients with SAD was
older than non-SAD patients (median age¼ 41 vs 34,
P< .01). Among these, 143 were identified with diagnosis
of CRS. SAD was present in 20% (n¼ 62) among the
whole group, among which 31% (11/35) had adequate
response to PCV. The prevalence of SAD was increased
in CRS (26%, n¼ 37) and RAS (18%, n¼ 11) compared
to RU (11%, n¼ 6) and NI (14%, n¼ 10); (P<.05). The
prevalence of SAD among patients with asthma (21%,
28/134) or rhinitis (AR/NAR; 19%, 46/242) was not dif-
ferent compared to those without these conditions (19%,
46/242 or 23%,16/71, P> .6 for both).
Prevalence of Sinusitis and Allergic Conditions
Among 3 Immunological Groups
Among individual groups (Group A, B, C) patients with
CRS were represented in higher proportion in Group B
Figure 2. Prevalence of clinical conditions among different groups. A, Percentage of clinical conditions among Group A, B, and C. B,
Percentage of clinical conditions among Group AB versus C. C, Percentage of clinical conditions among Group A versus BC.
CRS, chronic rhinosinusitis; Group A, adequate baseline-PAs; Group B, inadequate baseline-PAs with adequate post-PAs, responders;
Group C, inadequate baseline- and post-PAs, SAD; Group AB, Group AþGroup B: the groups with post-pPA 70%; Group BC, Group
BþGroup C: the group with baseline-pPA <70%; PA, pneumococcal antibody; SAD, specific antibody deficiency; URI, upper respiratory
infection.
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and C as compared to Group A (47% and 60% vs 26%,
P< .01; Table 1 and Figure 2(A)). Group A contained
higher proportion of patients with RUs (P< .05). The
prevalence of rhinitis, asthma, and allergic asthma was
not different among the groups, but allergy skin sensiti-
zation and allergic rhinitis were more common among
Group B compared to Group A (P< .05).
Impact of Baseline-pPA and SAD on Clinical
Conditions
Between Group A (adequate baseline-pPA) versus
Group BC (inadequate baseline-pPA; Figure 2(C) and
Table 2): The percentage of CRS was higher among
Group BC (P< .001). Group A contained higher per-
centage of patients with RU (P <.001). The prevalence
of allergic sensitization and AR were increased in Group
BC (P <.05).
Between SAD group (Group C) and non-SAD group
(Group AB; Figure 2(B) and Table 3): The percentage of
CRS was higher in SAD group (P< .05). The percen-
tages of patients with allergic conditions were not differ-
ent between the 2 groups.
Patterns of Recurrent Sinusitis During the 1 Year
Following the Initial Visit Among 3 Immunological
Groups of Sinusitis Patients
Among 143 patients with CRS, there were significant
differences in the recurrence of sinusitis based on
the use of antibiotics among Groups A, B, and C
(Figure 3 and Table 4). Group A had the lowest percent-
age of patients with recurrence requiring antibiotic treat-
ment (10%). The percentage of patients with recurrence
of sinusitis was higher in Group B even after pPAs were
normalized (40%), although P value did not reach
the significance (P¼ .09, probably due to small number
of subjects in Group A). Finally, Group C had the high-
est percentage of patients with recurrences (76%)
(Group A vs B: P¼ .088, Group A vs C: P< .001,
Group B vs C: P< .001) and higher trend for sinus sur-
gery (Group B vs C: P¼ .09, numbers too small). In
Group C, patients with inadequate response to PCV
had more severe courses requiring more antibiotics and
immunoglobulin replacement compared to nonres-
ponder, although the numbers were too small for
statistics.
Baseline-pPA as a Predictor for Post-PA Responses
A large proportion of our subjects had inadequate
baseline-pPAs (Group BC/total subjects¼ 81%) regard-
less of prior immunization history (Table 1). The median
baseline-pPAs were 0.85, 0.35, and 0.21 for Groups A,
B, and C, respectively (with P< .01 between Group A
and C, P¼ .01 between Groups B and C). The preva-
lence of SAD was inversely related to baseline-pPA, sug-
gesting patients with decreased baseline-pPA were more
Table 2. Demographics and Clinical/Laboratory Characterization
of Study Subjects by Postvaccination Responses: Group A versus
Group BC (Inadequate Baseline-pPA vs Adequate Baseline-pPA).
Group A:
Adequate
Baseline-pPA
Group BC:
Inadequate
Baseline-pPA
P
value
Patient cohort (%) 58 (24) 255 (76)
Median age 31 37 .80
Ethnicity (white /other) 51/7 217/38 .58
Male/female 15/43 96/159 .09
Recurrent infection (%) 43 (74) 198 (78) .57
No infection (%) 15 (26) 47 (22) .35
Chronic rhinosinusitis (%) 15 (26) 128 (50) .001
Recurrent acute sinusitis (%) 12(21) 49 (19) .80
Recurrent upper
respiratory infection (%)
20(34) 40 (16) .001
Allergy sensitization (%) 29(50) 165 (65) .04
Asthma (%) 25(43) 109 (43) .96
Allergic asthma (%) 13 (22) 87 (34) .08
Rhinitis (allergic and
nonallergic) (%)
43 (74) 199 (78) .52
Allergic rhinitis (%) 26 (45) 151 (59) .04
Abbreviation: pPA, percentage of protective (1.3mg/mL) pneumococcal
antibody serotypes/total tested serotypes.
Note: Bold values indicate statistical significance.
Table 3: Demographics and Clinical/Laboratory Characterization
of Study Subjects by Postvaccination Responses: SAD (Group C,
inadequate post-pPA) versus Non-SAD (Group AB, adequate
post-pPA).
Group AB:
Adequate
Baseline-pPA
(Non-SAD)
Group C:
Adequate
Post-pPA
(SAD)
P
value
Patient cohort (%) 251 (80) 62 (20)
Median age 34 41 .003
Ethnicity (white /other) 214/37 54/8 .71
Male/female 88/163 23/39 .76
Recurrent infection (%) 189 (75) 52 (84) .15
No infection (%) 62 (25) 10 (16) .2
Chronic rhinosinusitis (%) 106 (42) 37 (60) .014
Recurrent acute sinusitis (%) 50 (20) 11 (18) .70
Recurrent upper
respiratory infection (%)
53(21) 7 (11) .08
Allergy sensitization (%) 94 (37) 25 (40) .68
Asthma (%) 106 (42) 28 (45) .68
Allergic asthma (%) 79 (31) 21 (34) .72
Rhinitis (allergic and
nonallergic) (%)
196 (78) 46 (74) .51
Allergic rhinitis (%) 146 (58) 31 (50) .25
Abbreviations: pPA, percentage of protective (1.3lg/mL) pneumococcal
antibody serotypes/total tested serotypes; SAD: specific antibody defi-
ciency.
Note: Bold values indicate statistical significance.
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likely to develop SAD (Figure 4; odds ratio¼ 2.02, 95%
CI: 1.15–3.57, P¼ .01, n¼ 255).
Pattern of Inadequate Baseline PA Titers to Individual
Isotypes in 3 Immunological Groups
Among 23 serotypes, inadequate baseline PAs to sero-
type 3,19, and 23 distinguished Group C from Group B
and Group A (P< .05) and, of note, an inadequate titer
of serotype 3 was the most important predictor of SAD
(with Bonferroni-adjusted P value¼ .017). The frequen-
cies of inadequate baseline-PA to serotype 3 were 7%
(n¼ 4) in Group A, 44% (n¼ 84) in Group B, and 65%
(n¼ 40) in Group C (Table 5).
Discussion
Our analyses found the prevalence of SAD in the range
of 14% to 26% depending on the parameter used in line
with the literature.10–12 The prevalence of SAD was
higher in our patients with respiratory symptoms com-
pared to the one reported for asymptomatic subjects
(11%)10 and higher with CRS as compared to patients
with only RAS or URIs or NI. It is also important to
note that a high percentage (81%) of patients with recur-
rent upper respiratory symptoms had low baseline PAs
and the majority of whom benefitted from vaccination as
evidenced by a lower rate of recurrent sinusitis in the
following year (Figure 3 and Table 4).
Although efforts to establish the minimum threshold
for post-PA response have been made, no clear guide-
lines exist on PA threshold for adequate immune status
at the initial evaluation. Our analysis demonstrates that
prevalence of respiratory infections in our patients
depends on the level of PA at a given time. Although
the working group guidelines recommended using the
serotypes present only in PPV in patients who received
PCV,4 we used the total reported serotypes regardless of
their vaccination status, because we believe that those
represents more accurately the current state of vaccine
and infection induced immunity. Patients with inade-
quate pPA (Group A, Group B, and Group BC) have
history of more frequent CRS and RS, compared to ones
in Group A (Figure 2(C)) suggesting that pPA at the
initial visit reflected the recent state of poor immunity
against the bacteria. Group B even after normalization
of PA by vaccination (despite no difference in the aver-
age baseline-pPA of Group A and post-pPA of Group
B: 0.87 vs 0.89) tended to have more incidence of sinus-
itis over the next year compared to Group A. This sug-
gests a persistence of underlying B-cell deficiency. Our
analysis predicts that subjects with lower baseline-pPA
would have higher probability of qualifying for SAD
and more prone for CRS (Figure 4).
Our study demonstrated that vaccine responders
experienced lesser incidence of CRS (Figure 2, Table 4)
Table 4. Recurrence of Sinusitis (Antibiotics Treatment) in 1-Year Follow-up of Patients Who Presented With Sinusitis (n¼ 143).
Group n Abx rx-1 Abx rx-2þ
Patients
Treated
With Abx in
the Next Year
Total
Number
of Abx
(Average/
Patient)
Patients With
Adequate
Response
to PCVa Surgery
Prophylactic
Abx Ig Rx
No
Follow-up
A 15 1/10 (10%) 0 1 (10%) 1 (0.1) 0 5/15 (33%)
B 91 30/86 (34%) 4/86 (5%) 34/86 (40%) 38/86 (0.40) 2/86 (2%) 5/91 (5%)
C 37 13/33 (40%) 12/33 (36%) 25/33 (76%) 37/33 (1.1) 8/22 4/33 (12%) 4/33 (12%) 3/33 (9%) 4/37 (11%)
Abbreviations: abx rx-1, antibiotic treatment once in the next 1 year; abx rx-2þ, antibiotics treatment twice or more in the next 1 year; Ig rx, immu-
noglobulin replacement therapy; n, number of patients.
P value for difference of recurrences among groups (Fisher test): Among Group A versus Group B: <.001, Group A versus Group B¼ .088, Group A versus
Group C< .001.
aAll 37 patients were given PCV. Among these, 33 returned for follow-up appointments, and 22 had postvaccination PA titers tested; 14 of 22 had inadequate
responses. These nonresponders compared to responders (n¼ 8) had more severe clinical courses (P value not done due to small numbers).
Nonresponders (n¼ 14): Total number of abx, 15; surgery, 2; Ig rx¼ 3. Responders (n¼ 8): Total number of abx, 6; surgery, 2; Ig rx¼ 1.
Figure 3. Percentage of patients with CRS during the 1 year after
the initial visit (n¼ 143). A, Group A (adequate baseline-PAs); B,
Group B (inadequate baseline-PAs with adequate post-PAs, res-
ponders); C, Group C (inadequate baseline- and post-PAs, SAD);
n, number of patients who returned for follow-up visits.
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as previously reported in the literature.10,13–16 This indi-
cates the importance of an adequate number of protec-
tive titers against S. pneumoniae in the prevention of
recurrent or prolonged symptoms since S. pneumoniae
is a major pathogen for sinusitis and PAs represent
B-cell function against polysaccharide surface antigens
present on other major pathogenic bacteria such as
Haemophilus influenzae and Moraxella catarrhalis.17,18
Among recurrent respiratory infections, CRS was the
most common condition, often accompanied by RAS
and RU, and was most significantly associated with
inadequate baseline-pPA. The presence of RAS or
RU in the absence of CRS did not show a strong asso-
ciation. CRS (with or without nasal polyps) is generally
considered an inflammatory process with concomitant
bacterial infection/colonization of the sinus cavities.19,20
Poor ability of B cells to respond to polysaccharide anti-
gens as well as Th2 (allergic) bias in the host upper
airway may be contributory.20,21 Patients with inade-
quate baseline-pPA experienced significantly less RUs
Table 5. Number of Patients With Adequate Baseline-pPA to Individual Serotypes in Group A, B, and C.
Strainsa
Number of
Patients
in Group A
Number of
Patients
in Group B
Number of
Patients With
Group C
Overall
P Value
P Value:
Group
A vs B
P Value:
Group
A vs C
P Value:
Group
B vs C
Strain 1 <.0001 <.0001 <.0001 .458
1 3 110 32
0 55 83 30
Strain3 <.0001 <.0001 <.0001 .004
1 54 109 22
0 4 84 40
Strain4 <.0001 <.0001 <.0001 .4395
1 36 35 14
0 22 158 48
Strain5 <.0001 <.0001 <.0001 .5028
1 53 84 30
0 5 109 32
Strain8 <.0001 <.0001 <.0001 .1574
1 52 62 26
0 6 131 36
Strain9 <.0001 <.0001 <.0001 .7508
1 54 49 17
0 4 144 45
Strain12 <.0001 <.0001 .0155 .2725
1 24 29 13
0 34 164 49
Strain14 <.0001 <.0001 <.0001 .1759
1 57 100 26
0 1 93 36
Strain19 <.0001 <.0001 <.0001 .0306
1 56 129 32
0 2 64 30
(continued)
Figure 4. Probability of SAD based on baseline-pPA. Logistic
regression test was used with inadequate baseline-pPAs from
Group B and C as the independent variable (x-axis) and probability
of SAD (%) as the dependent variable (y-axis). The data showed
that the lower the baseline PA, the higher the probability of SAD
(odds ratio¼ 2.02, 95% CI: 1.15–3.57, P¼.01, n¼ 37). pPA, per-
centage of protective (1.3 mg/mL) pneumococcal antibody sero-
types to total tested serotypes; SAD, specific antibody deficiency.
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probably suggesting that RU evolved into CRS or RAS
rather than staying as an isolated event.
The prevalence of allergic sensitization was much
more common among our population with CRS, RAS,
or RU (60%), which is consistent with previous epide-
miological data.11 This is far above the rate of allergic
sensitization among the general population as reported
by NHANES: 45% in patients aged 6 years or older.22
The prevalence rates of asthma (42%) and rhinitis (77%)
were also higher in our total study group as compared to
the general population (7%–8% and 20%–30% in the
United States).23–25 Although it is tempting to postulate
that allergic sensitization might suppress PA response to
natural exposures, our data are conflicting as in the
Table 5. Continued
Strainsa
Number of
Patients
in Group A
Number of
Patients
in Group B
Number of
Patients With
Group C
Overall
P Value
P Value:
Group
A vs B
P Value:
Group
A vs C
P Value:
Group
B vs C
Strain23 <.0001 <.0001 <.0001 .0361
1 56 85 18
0 2 108 44
Strain26 <.0001 <.0001 <.0001 .8752
1 53 80 25
0 5 113 37
Strain51 <.0001 <.0001 <.0001 .1163
1 55 84 20
0 3 109 42
Strain56 <.0001 <.0001 .0765
1 39 77 17
0 19 116 45
Strain68 <.0001 <.0001 <.0001 .2066
1 56 61 25
0 2 132 37
Strain17 <.0001 <.0001 <.0001 .9187
1 58 129 41
0 . 64 21
Strain2 .0168 .0043 .0576 .4715
1 48 121 42
0 10 72 20
Strain20 .0023 .0005 .0036 .8364
1 52 128 42
0 6 65 20
Strain22 .0009 .0002 .0002 .9187
1 53 129 41
0 5 64 21
Strain34 <.0001 <.0001 .0006 .3689
1 55 125 44 <.0001
0 3 68 18
Strain43 .9674 .7968 .8733 .9477
1 41 133 43
0 17 60 19
Strain54 .0057 .0014 .00081 .8364
1 51 128 42
0 7 65 20
Strain57 .0004 .0001 .0002 .8102
1 56 140 44
0 2 53 18
Strain70 .0009 .0017 .0002 .1796
1 52 133 37
0 6 60 25
aStrains: 1¼ protective, 0¼ nonprotective.
Note: Bold values indicate statistical significance.
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literature.10,26 There is a tendency for higher prevalence
of allergic sensitization and AR among patients with low
pre-PA (Group BC, P< .05). However, when all patients
were divided into allergy-sensitized versus nonsensitized
group, there was no significant difference in the preva-
lence of SAD (19% vs 19%) or CRS (41% vs 53%). This
contradiction may be explained on the statistical basis.
As seen in Figure 2(A), the allergic sensitization was
highest in Group B and lowest in Group A. When
patients were divided into SAD (Group C) and non-
SAD (Group AB) as in Figure 2(B), Group B with the
largest number of cohorts might have raised the rate of
allergic sensitization for non-SAD group matching that
of SAD group.
The pneumococcal polysaccharide capsule is crucial
for virulence, primarily by protecting the bacteria
against phagocytosis. Serotype 3 is reportedly more
immunogenic in young children who are not able to
respond to other serotypes.4,27 Our data indicate that
inadequate titers to a few serotypes, in particular, to
serotype 3, may be a useful predictor of SAD.
Contribution of individual or congregational serotypes
to the SAD characteristics is not completely understood
at this point. These findings needs to be confirmed, since
previous efforts to identify selected serotype as repre-
senting larger number of serotypes have failed.28
In summary, patients with symptoms of recurrent
respiratory symptoms presenting with inadequate
baseline-pPA and serotype 3 titer have higher chance
of current CRS and not responding to PPV. The lower
the initial pPA, the higher chance for SAD and develop-
ing CRS subsequently even after normalization of pPA.
Further studies are needed to confirm our findings and
to identify the potential genetic defects associated with
this condition.
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